This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, the Netherlands, Poland, Romania, Slovakia, Sweden, the United Kingdom, and the United States.
This study is looking at evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with depression for people with depression. Taking part may give some people access to NBI-1065845, but direct benefit is not guaranteed.
The official record suggests in-person participation through a clinic, with sites including Neurocrine Clinical Site in Little Rock, Neurocrine Clinical Site in Orange, and Neurocrine Clinical Site in Pico Rivera. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and having a stable enough treatment background for the study, while common reasons not to take part include safety concerns that need urgent care first and other treatments that could interfere with the study. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Belgium.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring observational follow-up for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Neurocrine Biosciences, a biotech company. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company. The sponsor is based in the United States. Sponsor website: https://www.neurocrine.com. You can verify the sponsor and study responsibility in the official registry record.
This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.